Technical Analysis for MRUS - Merus N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Volume Surge | Other | -7.09% | |
| Upper Bollinger Band Walk | Strength | -7.09% | |
| Wide Bands | Range Expansion | -7.09% | |
| Above Upper BB | Strength | -7.09% | |
| Gapped Up | Strength | -7.09% | |
| Upper Bollinger Band Touch | Strength | -7.09% | |
| New Uptrend | Bullish | -1.41% |
| Alert | Time |
|---|---|
| Down 5% | 2 days ago |
| Down 1 ATR | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
| Possible Inside Day | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 61.61 |
| 52 Week Low | 19.805 |
| Average Volume | 915,436 |
| 200-Day Moving Average | 33.40 |
| 50-Day Moving Average | 45.41 |
| 20-Day Moving Average | 48.01 |
| 10-Day Moving Average | 49.81 |
| Average True Range | 3.34 |
| RSI (14) | 59.02 |
| ADX | 30.76 |
| +DI | 38.27 |
| -DI | 12.22 |
| Chandelier Exit (Long, 3 ATRs) | 51.59 |
| Chandelier Exit (Short, 3 ATRs) | 52.62 |
| Upper Bollinger Bands | 57.86 |
| Lower Bollinger Band | 38.15 |
| Percent B (%b) | 0.77 |
| BandWidth | 41.06 |
| MACD Line | 2.61 |
| MACD Signal Line | 1.54 |
| MACD Histogram | 1.0684 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 61.05 | ||||
| Resistance 3 (R3) | 61.76 | 59.87 | 59.75 | ||
| Resistance 2 (R2) | 59.87 | 57.88 | 59.51 | 59.31 | |
| Resistance 1 (R1) | 56.56 | 56.65 | 55.61 | 55.84 | 58.88 |
| Pivot Point | 54.67 | 54.67 | 54.19 | 54.31 | 54.67 |
| Support 1 (S1) | 51.35 | 52.68 | 50.41 | 50.64 | 47.60 |
| Support 2 (S2) | 49.46 | 51.45 | 49.10 | 47.17 | |
| Support 3 (S3) | 46.15 | 49.46 | 46.73 | ||
| Support 4 (S4) | 45.43 |
